Andrea Newbold
Grattan Street
Melbourne, VIC 3000, Australia
Melbourne, VIC 3000, Australia
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 27 publications
Dual Bcl-2/Bcl-xl inhibition via AZD0466 combines with immune checkpoint blockade to enhance anti-tumour activity.
Journal: Cell death & disease
Published: September 04, 2024
Rationally designed chimeric PI3K-BET bromodomain inhibitors elicit curative responses in MYC-driven lymphoma.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: August 29, 2023
Stepwise progression of β-selection during T cell development involves histone deacetylation.
Journal: Life science alliance
Published: August 03, 2022
The Combination of Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Delays KMT2A-Rearranged Leukemia Progression.
Journal: Frontiers in oncology
Published: January 27, 2022
Serine Biosynthesis Is a Metabolic Vulnerability in FLT3-ITD-Driven Acute Myeloid Leukemia.
Journal: Cancer discovery
Published: May 23, 2020
AZD4320, A Dual Inhibitor of Bcl-2 and Bcl-xL, Induces Tumor Regression in Hematologic Cancer Models without Dose-limiting Thrombocytopenia.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: March 19, 2020
Corrigendum: Detection of Apoptotic Cells Using Propidium Iodide Staining.
Journal: Cold Spring Harbor protocols
Published: June 03, 2018
Inhibitors of histone acetyltransferases KAT6A/B induce senescence and arrest tumour growth.
Journal: Nature
Published: December 10, 2016
BET Inhibition Induces Apoptosis in Aggressive B-Cell Lymphoma via Epigenetic Regulation of BCL-2 Family Members.
Journal: Molecular cancer therapeutics
Published: November 15, 2015
Last Updated: 09/26/2026